First treatment for advanced colorectal cancer with combo chemo
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced colorectal cancer that cannot be removed by surgery or has spread to other parts of your body.
- You should not have received any chemotherapy or other treatment specifically for this advanced cancer.
- You need to be between 18 and 75 years old and able to walk around and take care of yourself (ECOG 0-2).
- Your kidney and liver function must be fairly normal, and your blood counts need to be high enough for chemotherapy.
- You cannot have a tumor type called MSI-H or dMMR, which would make this treatment less effective.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
This trial is testing a new combination of three drugs (cetuximab, envolimab, and a chemo called mFOLFOX6) for people with advanced colorectal cancer that has not been treated yet. The goal is to see if this combination is safe and works better than standard treatments.
This trial tests a different way of giving a chemotherapy drug called irinotecan, along with two other drugs (5-FU and bevacizumab), for people whose cancer got worse after first-line treatment. It aims to see if this combination can help control the cancer.
This trial tests a new combination of drugs as the first treatment for small bowel adenocarcinoma that has spread or can't be removed with surgery. It aims to see if this approach can help control the cancer and improve outcomes.
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.